Primary FibromyalgiaPhase 2NCT03783910
Efficacy and Safety of GRT9906 Tablets Compared to Placebo in Patients With Fibromyalgia
A Phase 2 study testing GRT9906 in people with Primary Fibromyalgia, run by Grünenthal GmbH at 6 sites in United States.
Trial summary
The study was performed in participants suffering from fibromyalgia and investigated efficacy after treatment with several doses of GRT9906 versus placebo. Furthermore, it was to be found out if treatment with GRT9906 was safe and well-tolerated. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Primary Fibromyalgia
- What is being tested?
- GRT9906
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 90 participants
- Where
- 6 sitesUnited States
- Study dates
- 19 Sep 2005to 20 Oct 2006
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female ambulatory participants of any ethnic group, aged 18 to 75 years inclusive at enrollment.
- Primary fibromyalgia syndrome (FMS) diagnosed according to the American College of Rheumatology (ACR) 1990 criteria, persistent for at least 6 months.
- Average Pain Intensity of FMS pain over the last 3 days before randomization visit must be at least 4 points, using 11-point numerical rating scale (NRS).
- Negative urine test for drugs of abuse at the Day 1 visit of each treatment period.
- Women of childbearing potential must use an acceptable method of contraception (i.e., double barrier, hormonal or intra-uterine device method) during the study period and have a negative urine pregnancy test at the Enrollment Visit and at the Day 1 visit of each treatment period.
- Compliance with use and completion of assessments by means of electronic diaries; 80 percent of entries must be available for the week before randomization.
- Written informed consent for study participation given.
Who cannot join
- Participation in another study of IMPs or devices parallel to, or less than 1 month prior to enrollment, or previous participation in this study.
- Known to or suspected of not being able to comply with the study protocol and the use of the IMPs.
- Not able to communicate meaningfully with the Investigator and staff.
- Evidence or history of alcohol, medication or drug dependency during the past 12 months. History of opiate dependency at any point in life.
- Evidence or history of neurotic personality, psychiatric illness including anxiety disorder, severe senile dementia, Alzheimer's disease, history of seizures or pre-existing conditions that lower seizure threshold (e.g., head trauma), or suicide risk.
- Current depression needing treatment with antidepressants.
Show all 28Show fewer
- Currently or previously diagnosed with malignancies except basal cell carcinoma; poor medical status (e.g., New York Heart Association [NYHA] class equal to or above 3; Child classification for hepatic impairment above A [Pugh et al. 1973]; decompensated chronic obstructive pulmonary disease) or, at the discretion of the Investigator, clinical signs that raise concerns about participant's suitability for the study.
- Creatinine higher than 1.5-times of upper limit of normal (ULN) range.
- Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) higher than twice the ULN range.
- Any chronic disease (e.g., hepatic, renal and/or gastrointestinal) that might affect drug absorption, metabolism or excretion.
- Nursing mother.
- Causes of chronic pain other than FMS and mild osteoarthritis of the hand.
- Proven rheumatoid disease with positive rheumatoid factor or antinuclear antibody (ANA) at screening.
- History of marked repolarization abnormality (e.g., suspicion of or definite congenital long QT syndrome).
- QT values of: corrected QT Bazett (QTcB) females equal to or above 450 milliseconds (ms), QTcB males equal to or above 430 ms, uncorrected QT equal to or above 500 ms at Enrollment Visit.
- Definite or suspected allergy or hypersensitivity to drugs having a similar mechanism of action as IMP. Known contraindications/hyper-sensitivity to opioids, acetaminophen or zolpidem.
- Intolerance to galactose.
- Dysphagia or difficulty swallowing tablets or capsules.
- Blood donation (above 100 milliliters) or comparable blood losses within 3 months prior to the start of this study.
- History of Gilbert's Disease.
- Use of anti-epileptic drugs, chloramphenicol, rifampicin, or zidovudine.
- Use of fentanyl transdermal system, buprenorphine sublingual or transdermal system, cyclooxygenase (COX) 2 inhibitors with a half-life of more than 35 hours, equal to or less than 7 days prior to enrollment.
- Use of serotonergic drugs, drugs with the potential to prolong QT interval, cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) substrates, antiparkinson drugs, monoamineoxidase (MAO)-inhibitors, neuroleptics, or other drugs that may lower the seizure threshold, within less than 5 half-life times prior to randomization.
- Use of any analgesics (including non-steroidal anti-inflammatory drugs [NSAIDs] and COX2 inhibitors) others than investigational medicinal products and acetaminophen as rescue medication as well as sedative hypnotics (with the exception of 5 milligrams zolpidem for a maximum of 3 days per week) within less than 5 half-life times prior to randomization.
- Physical therapy and/or other non-pharmacological pain therapy (e.g., acupuncture, transcutaneous electrical nerve stimulation [TENS]) after Enrollment Visit if not started at least 6 months before enrollment.
- Systemic (parenteral and/or oral) steroids during previous month.
- Tender point injections (with local anesthetics or others) during the previous month.
- Participants currently involved in litigation regarding FMS, pending or active disability-compensation claim.
Trial locations and contacts
6 sites in 1 country.
6 sites in 1 country
United States6 sites
005 Research Facility
Charlotte, North Carolina, 28210
006 Research Facility
DeLand, Florida, 32720
004 Research Facility
Medford, Oregon, 97504
002 Research Facility
Portland, Oregon, 97239
001 Research Facility
San Antonio, Texas, 78213
003 Research Facility
San Antonio, Texas, 78229
About this study
Official title: Cross-over Multiple Dose Study Assessing the Analgesic Efficacy and Safety of Oral GRT9906 Compared to Placebo in Subjects With Primary Fibromyalgia Syndrome
The study was performed in participants suffering from fibromyalgia and investigated efficacy after treatment with several doses of GRT9906 versus placebo. Furthermore, it was to be found out if treatment with GRT9906 was safe and well-tolerated.
Read the detailed description
This Phase 2 study had a randomized, multi-center, double-blind, placebo-controlled, crossover, multiple-administration design.
The objectives of the study were the following:
- To assess the multiple-dose analgesic efficacy and safety of an oral prolonged-release (PR) tablet formulation of GRT9906 at daily doses between 80 and 240 milligrams (mg) in comparison to placebo in participants with moderate to severe pain due to primary fibromyalgia syndrome (FMS).
- To compare the tolerability of multiple-dose GRT9906 PR to placebo in participants with primary FMS.
- To generate data that could be used, in combination with data from other studies, to explore the population pharmacokinetic analysis and pharmacokinetic/pharmacodynamic (PK/PD) properties of GRT9906 PR.
The study consisted of 5 phases:
- Enrollment including tapering, if necessary, and washout (at least 1 week) of previous medication.
- First treatment period with 1-week titration and 5-weeks dosing on participant's last well-tolerated titration dosage.
- Interim washout period of at least 1 week.
- Second treatment period with 1-week titration and 5-weeks dosing on participant's last well-tolerated titration dosage.
- Final washout period of at least 1 week, terminated by a Follow-up Visit.
- Conditions
- Primary Fibromyalgia
- Being tested
- GRT9906, Placebo
- Keywords
- Chronic pain
- Medical subject headings
- Fibromyalgia, Chronic Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GRT9906Drug
One prolonged-release tablet containing 40 mg of GRT9906
PlaceboDrug
Placebo matching GRT9906 tablets
| Study group | Role | What they receive |
|---|---|---|
| GRT9906 | Experimental | Participants received 80-240 mg of GRT9906 oral for up to 6 weeks (1 week of titration, 5 weeks of maintenance treatment).
Participants started with 40 mg of GRT9906 on the first and 80 mg (40 mg twice daily) on the second day. They could increase the dose every day by 1 tablet (i.e., GRT9906 40 mg), up to a maximum daily dose of 240 mg (120 mg twice daily). Participants experiencing adverse events could reduce the dose to the next lower, better tolerated daily dose (but not lower than 80 mg [40 mg twice daily]). By Day 8, every participant had reached their optimal daily dose and was asked to continue on the identified dosing regimen for the following 5 weeks. Receives: Drug: GRT9906 |
| Placebo | Placebo comparator | Participants received Placebo (2-6 tablets daily) oral for up to 6 weeks. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Average Pain Intensity over last 3 days of treatment period
Participants recorded their daily current pain intensity in an electronic diary from the Enrollment Visit until the day of the last visit in the second treatment period using an 11-point Numerical Rating scale (NRS) ranging from 0 = no pain to 10 = pain as bad as you can imagine. Each treatment period lasted for 6 weeks. For the primary endpoint, the average daily current pain intensity over the last 3 days prior to the last visit per treatment period was calculated.
Measured: Last 3 days of treatment period
Secondary outcomes (19)
Changes from baseline/period baseline in Average Pain Intensity over last 3 days per treatment period
Participants recorded their daily current pain intensity in an electronic diary from the Enrollment Visit until the day of the last visit in the second treatment period using an 11-point Numerical Rating scale (NRS) ranging from 0 = no pain to 10 = pain as bad as you can imagine. Each treatment period lasted for 6 weeks. Changes from baseline/period baseline for the average daily current pain intensity over the last 3 days prior to the last visit per treatment period were calculated.
Measured: At baseline, at period baseline, and for last 3 days of each treatment period
Average Pain Intensity after initial washout and over Weeks 1 to 6 per treatment period
Participants recorded their daily current pain intensity in an electronic diary from the Enrollment Visit until the day of the last visit in the second treatment period using an 11-point Numerical Rating scale (NRS) ranging from 0 = no pain to 10 = pain as bad as you can imagine. Each treatment period lasted for 6 weeks. The average daily current pain intensities over the last 3 days of the initial washout period (before randomization) and over Weeks 1, 2, 3, 4, 5, and 6 per treatment period were calculated.
Measured: Last 3 days of the initial washout period; Week 1, 2, 3, 4, 5 and 6 per treatment period
Fibromyalgia Impact Questionnaire (FIQ)
The FIQ is a 10-item self-administered questionnaire measuring physical functioning, work status, depression, anxiety, sleep, pain, stiffness, fatigue, and well-being over a 1-week period. Each of the 10 items has a maximum possible score of 10 with a higher score indicating a greater impact of the syndrome on the patient. The FIQ total score is calculated by a weighted sum of the 10 items. The FIQ total score and sub-scores for FIQ items for fatigue, tiredness on awakening, and stiffness were calculated.
Measured: At Enrollment Visit (Visit 1), on Day 1, Day 22, and Day 42 per treatment period, and at Final Visit (14 days after last dose in treatment period 2)
Tender Point Index (TPI)
Digital palpation with an approximate force of 4 kg was applied at 18 tender point sites. A tenderness scale was applied to the tenderness at each tender point site examined: non-tender (0), tender without physical response (1), tender plus wince or withdrawal (2), exaggerated withdrawal (3), too painful to touch (4). The sum of the tenderness severities at all 18 sites was the TPI. The expected range for normal controls is 0-5, for participants with fibromyalgia 11-72.
Measured: At Enrollment Visit (Visit 1), on Day 1, Day 22, and Day 42 per treatment period, and at Final Visit (14 days after last dose in treatment period 2)
Average Pain Threshold (APT)
A Fischer algometer was used for this purpose. The foot piece was placed on the skin at the site of each tender point. The axis of the instrument was held firmly in place by a finger or thumb and vertical to the skin surface. The participant was informed that they "will at first feel only pressure but then it will change to pain". The participant was to say "now" at the exact time when the pressure feeling changed to a pain feeling. The algometer applied pressure was advanced at a rate of 1 kg/second. When the participant indicated "now" the examiner withdrew the instrument and read the gauge pressure in kg to one decimal place. A value was recorded for algometry at each of the 18 tender points. The average of these 18 values has been defined as the APT.
Measured: At Enrollment Visit (Visit 1), on Day 1, Day 22, and Day 42 per treatment period, and at Final Visit (14 days after last dose in treatment period 2)
Morning Stiffness Questionnaire (MSQ)
The duration of morning stiffness during the past 7 days was assessed by answering 3 questions, each with 5 categories of "no stiffness" and "1 hour", "2 hours", "3 hours", or "5 hours". Questions were "During the past 7 days, on average, how long did your morning stiffness last until it began to improve/maximum improvement occurred/how long did it take to get going properly?".
Measured: At Enrollment Visit (Visit 1), on Day 1, Day 22, and Day 42 per treatment period, and at Final Visit (14 days after last dose in treatment period 2)
Major Depression Inventory (MDI)
The MDI scale is a 10-item self-administered questionnaire for assessing major depression according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) and International Classification of Diseases (ICD-10) as well as measuring severity of depressive states. Each item is scored on a Likert scale from 0 to 5. Treatment outcome is measured by the sum of the 10 individual items. In addition to the total score, a MDI rating scale was defined as follows: No sign of Depression: MDI total score below 20; Mild Depression: MDI total score of 20 to 24; Moderate Depression: MDI total score of 25 to 29; Severe Depression: MDI total score of 30 and more.
Measured: At Enrollment Visit (Visit 1), on Day 1, Day 22, and Day 42 per treatment period, and at Final Visit (14 days after last dose in treatment period 2)
Change from baseline in Sleep Problem Scale (SPS) total score
The SPS is a 4-item questionnaire assessing sleep problems over a 1-month period, covering the following dimensions: delay of sleep onset, difficulty staying asleep, awakening too early, and tiredness after usual amount of sleep. Response categories comprised: Not at all (score 0), 1-3 days (1), 4-7 days (2), 8-14 days (3), 15-21 days (4), and 22-31 days (5). The SPS total score is calculated as the sum of the 4 individual items. Greater levels of sleep problems are indicated by higher scores. The SPS total score is calculated as the sum of the 4 individual items. Changes from baseline (Visit 1) for the SPS total score at Day 42 are calculated per treatment period.
Measured: At Enrollment Visit (Visit 1) and on Day 42 per treatment period
30 percent reduction in pain based on Average Pain Intensity (API)
The number of participants who achieved a 30 percent reduction in pain is calculated based on the API recorded prior to the last visit in each treatment period. The dichotomous variable (yes/no) is calculated separately for each period. A participant with at least a 30 percent reduction in pain from period/overall baseline is coded as 30 percent reduction = Yes.
Measured: Prior to the last visit in each treatment period (Day 42)
50 percent reduction in pain based on Average Pain Intensity (API)
The number of participants who achieved a 50 percent reduction in pain is calculated based on the API recorded prior to the last visit in each treatment period. The dichotomous variable (yes/no) is calculated separately for each period. A participant with at least a 50 percent reduction in pain from period/overall baseline is coded as 50 percent reduction = Yes.
Measured: Prior to the last visit in each treatment period (Day 42)
Number needed to treat (NNT) for 30 percent reduction in pain
The number of participants needed to be treated with GRT9906 to achieve 1 additional participant with a 30 percent reduction in pain prior to the last visit in each treatment period was calculated based on the number of participants with a 30 percent reduction in API values.
Measured: Prior to the last visit in each treatment period (Day 42)
Number needed to treat (NNT) for 50 percent reduction in pain
The number of participants needed to be treated with GRT9906 to achieve 1 additional participant with a 50 percent reduction in pain prior to the last visit in each treatment period was calculated based on the number of participants with a 50 percent reduction in API values.
Measured: Prior to the last visit in each treatment period (Day 42)
Quality of sleep using the Sleep Problem Scale (SPS)
The SPS total score is calculated as the sum of the 4 individual items. Change will be calculated by subtracting the SPS total score obtained at baseline (Visit 1) from the SPS total score obtained at Day 42 per treatment period.
Measured: At Visit 1 and on Day 42 of each treatment period
Subject's Global Assessment of the investigational medicinal product (IMP)
The participant rated their overall impression of the IMP at Day 42 or final visit per treatment period. They were asked the following questions on a 5-point verbal rating scale (VRS): "How would you rate the IMP you received for pain?" Excellent (4), Very Good (3), Good (2), Fair (1), Poor (0). Frequencies per category were calculated.
Measured: On Day 42 of each treatment period
Investigator's Global Assessment of the investigational medicinal product (IMP)
Physicians rated their overall impression of the IMP at Day 42 or final visit per treatment period. They were asked the following questions on a 5-point VRS: "How would you rate the IMP the subject received for pain?" Categories were Excellent (4), Very Good (3), Good (2), Fair (1), Poor (0). Frequencies per category were calculated.
Measured: On Day 42 of each treatment period
Patient's Global Impression of Change (PGIC)
Participants rated their overall impression of change on a 7-point VRS: "Compared to your pain at admission to the project, how much has it changed?" Categorical scales are: Very much improved (1), Much improved (2), Minimally improved (3), No change (4), Minimally worse (5), Much worse (6), Very much worse (7). Frequencies per category are calculated.
Measured: On Day 42 of each treatment period
Mean daily number of rescue medication tablets taken
Rescue medication (acetaminophen up to 2 grams per day) was allowed in the study. The mean daily amount (mg/day) was determined per treatment period.
Measured: From Day 1 to Day 42 over each treatment period
Total amount of rescue medication taken
Rescue medication (acetaminophen up to 2 grams per day) was allowed in the study. The total amount (mg) was determined per treatment period.
Measured: From Day 1 to Day 42 over each treatment period
Clinical Opiate Withdrawal Scale (COWS)
Withdrawal symptoms were assessed using the COWS questionnaire. It comprises 11 items (resting pulse while sitting or lying for 1 minute, gastrointestinal upset over last half hour, sweating over past half hour, tremor observed with outstretched hands, restlessness during assessment, yawning during assessment, pupil size, anxiety or irritability, bone or joint aches attributed to opiate withdrawal, gooseflesh skin, runny nose or tearing not accounted for by cold symptoms or allergies) that best describe the participants' signs or symptoms. Point values of each answer to be included in the total score vary between 0 and 5 (the higher the value the worse). The sum of all 11 items is rated as follows: 5-12 = mild, 13-24 = moderate, 25-36 = moderately severe, above 36 = severe withdrawal.
Measured: At Visit 1 and Day 45 (2-4 days after last day of intake of IMP per treatment period)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Dec 2018
- Study start19 Sep 2005
- Primary completionOct 2006
- Study completion20 Oct 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Primary FibromyalgiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- This dose-titration study was conducted with randomized, multi-center, double-blind, placebo-controlled, crossover design and multiple administrations in 2 treatment sequences in treatment periods 1 and 2: Sequence GRT9906-Placebo and sequence Placebo-GRT9906.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- Grünenthal GmbH
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Grünenthal Study Director, Study director, Grünenthal GmbH
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03783910
- Sponsor's protocol ID
- KF9906/03
- Status last verified
- Dec 2018
- First submitted
- 18 Dec 2018
- Last updated
- 21 Dec 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973 Aug;60(8):646-9. doi: 10.1002/bjs.1800600817. No abstract available.
PubMed 4541913
Study at a glance
From the registry record, last updated by the sponsor on 21 Dec 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cross-over Multiple Dose Study Assessing the Analgesic Efficacy and Safety of Oral GRT9906 Compared to Placebo in Subjects With Primary Fibromyalgia Syndrome
- ClinicalTrials.gov ID
- NCT03783910
- Acronym / sponsor ID
- KF9906/03
- Conditions
- Primary Fibromyalgia
- Keywords
- Chronic pain
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- Grünenthal GmbHIndustry (pharma, biotech, devices)
- Study start
- 19 Sep 2005 (actual)
- Primary completion
- Oct 2006 (actual)
- Study completion
- 20 Oct 2006 (actual)
- First posted
- 21 Dec 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study was performed in participants suffering from fibromyalgia and investigated efficacy after treatment with several doses of GRT9906 versus placebo. Furthermore, it was to be found out if treatment with GRT9906 was safe and well-tolerated.
Detailed description
This Phase 2 study had a randomized, multi-center, double-blind, placebo-controlled, crossover, multiple-administration design.
The objectives of the study were the following:
- To assess the multiple-dose analgesic efficacy and safety of an oral prolonged-release (PR) tablet formulation of GRT9906 at daily doses between 80 and 240 milligrams (mg) in comparison to placebo in participants with moderate to severe pain due to primary fibromyalgia syndrome (FMS).
- To compare the tolerability of multiple-dose GRT9906 PR to placebo in participants with primary FMS.
- To generate data that could be used, in combination with data from other studies, to explore the population pharmacokinetic analysis and pharmacokinetic/pharmacodynamic (PK/PD) properties of GRT9906 PR.
The study consisted of 5 phases:
- Enrollment including tapering, if necessary, and washout (at least 1 week) of previous medication.
- First treatment period with 1-week titration and 5-weeks dosing on participant's last well-tolerated titration dosage.
- Interim washout period of at least 1 week.
- Second treatment period with 1-week titration and 5-weeks dosing on participant's last well-tolerated titration dosage.
- Final washout period of at least 1 week, terminated by a Follow-up Visit.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- This dose-titration study was conducted with randomized, multi-center, double-blind, placebo-controlled, crossover design and multiple administrations in 2 treatment sequences in treatment periods 1 and 2: Sequence GRT9906-Placebo and sequence Placebo-GRT9906.
| Arm | Type | Receives |
|---|---|---|
| GRT9906 | Experimental | Drug: GRT9906Participants received 80-240 mg of GRT9906 oral for up to 6 weeks (1 week of titration, 5 weeks of maintenance treatment). Participants started with 40 mg of GRT9906 on the first and 80 mg (40 mg twice daily) on the second day. They could increase the dose every day by 1 tablet (i.e., GRT9906 40 mg), up to a maximum daily dose of 240 mg (120 mg twice daily). Participants experiencing adverse events could reduce the dose to the next lower, better tolerated daily dose (but not lower than 80 mg [40 mg twice daily]). By Day 8, every participant had reached their optimal daily dose and was asked to continue on the identified dosing regimen for the following 5 weeks. |
| Placebo | Placebo comparator | Drug: PlaceboParticipants received Placebo (2-6 tablets daily) oral for up to 6 weeks. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Male or female ambulatory participants of any ethnic group, aged 18 to 75 years inclusive at enrollment.
- Primary fibromyalgia syndrome (FMS) diagnosed according to the American College of Rheumatology (ACR) 1990 criteria, persistent for at least 6 months.
- Average Pain Intensity of FMS pain over the last 3 days before randomization visit must be at least 4 points, using 11-point numerical rating scale (NRS).
- Negative urine test for drugs of abuse at the Day 1 visit of each treatment period.
- Women of childbearing potential must use an acceptable method of contraception (i.e., double barrier, hormonal or intra-uterine device method) during the study period and have a negative urine pregnancy test at the Enrollment Visit and at the Day 1 visit of each treatment period.
Key exclusion criteria (28 listed)
- Participation in another study of IMPs or devices parallel to, or less than 1 month prior to enrollment, or previous participation in this study.
- Known to or suspected of not being able to comply with the study protocol and the use of the IMPs.
- Not able to communicate meaningfully with the Investigator and staff.
- Evidence or history of alcohol, medication or drug dependency during the past 12 months. History of opiate dependency at any point in life.
- Evidence or history of neurotic personality, psychiatric illness including anxiety disorder, severe senile dementia, Alzheimer's disease, history of seizures or pre-existing conditions that lower seizure threshold (e.g., head trauma), or suicide risk.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GRT9906One prolonged-release tablet containing 40 mg of GRT9906 | Drug | GRT9906 |
| PlaceboPlacebo matching GRT9906 tablets | Drug | Placebo |
Primary outcome
Average Pain Intensity over last 3 days of treatment period
Time frame: Last 3 days of treatment period
Participants recorded their daily current pain intensity in an electronic diary from the Enrollment Visit until the day of the last visit in the second treatment period using an 11-point Numerical Rating scale (NRS) ranging from 0 = no pain to 10 = pain as bad as you can imagine. Each treatment period lasted for 6 weeks. For the primary endpoint, the average daily current pain intensity over the last 3 days prior to the last visit per treatment period was calculated.
19 secondary outcomes
Changes from baseline/period baseline in Average Pain Intensity over last 3 days per treatment period
Time frame: At baseline, at period baseline, and for last 3 days of each treatment period
Average Pain Intensity after initial washout and over Weeks 1 to 6 per treatment period
Time frame: Last 3 days of the initial washout period; Week 1, 2, 3, 4, 5 and 6 per treatment period
Fibromyalgia Impact Questionnaire (FIQ)
Time frame: At Enrollment Visit (Visit 1), on Day 1, Day 22, and Day 42 per treatment period, and at Final Visit (14 days after last dose in treatment period 2)
Tender Point Index (TPI)
Time frame: At Enrollment Visit (Visit 1), on Day 1, Day 22, and Day 42 per treatment period, and at Final Visit (14 days after last dose in treatment period 2)
Average Pain Threshold (APT)
Time frame: At Enrollment Visit (Visit 1), on Day 1, Day 22, and Day 42 per treatment period, and at Final Visit (14 days after last dose in treatment period 2)
Morning Stiffness Questionnaire (MSQ)
Time frame: At Enrollment Visit (Visit 1), on Day 1, Day 22, and Day 42 per treatment period, and at Final Visit (14 days after last dose in treatment period 2)
Major Depression Inventory (MDI)
Time frame: At Enrollment Visit (Visit 1), on Day 1, Day 22, and Day 42 per treatment period, and at Final Visit (14 days after last dose in treatment period 2)
Change from baseline in Sleep Problem Scale (SPS) total score
Time frame: At Enrollment Visit (Visit 1) and on Day 42 per treatment period
30 percent reduction in pain based on Average Pain Intensity (API)
Time frame: Prior to the last visit in each treatment period (Day 42)
50 percent reduction in pain based on Average Pain Intensity (API)
Time frame: Prior to the last visit in each treatment period (Day 42)
Number needed to treat (NNT) for 30 percent reduction in pain
Time frame: Prior to the last visit in each treatment period (Day 42)
Number needed to treat (NNT) for 50 percent reduction in pain
Time frame: Prior to the last visit in each treatment period (Day 42)
Quality of sleep using the Sleep Problem Scale (SPS)
Time frame: At Visit 1 and on Day 42 of each treatment period
Subject's Global Assessment of the investigational medicinal product (IMP)
Time frame: On Day 42 of each treatment period
Investigator's Global Assessment of the investigational medicinal product (IMP)
Time frame: On Day 42 of each treatment period
Patient's Global Impression of Change (PGIC)
Time frame: On Day 42 of each treatment period
Mean daily number of rescue medication tablets taken
Time frame: From Day 1 to Day 42 over each treatment period
Total amount of rescue medication taken
Time frame: From Day 1 to Day 42 over each treatment period
Clinical Opiate Withdrawal Scale (COWS)
Time frame: At Visit 1 and Day 45 (2-4 days after last day of intake of IMP per treatment period)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Dec 2018.
- Background: PubMed 4541913Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973 Aug;60(8):646-9. doi: 10.1002/bjs.1800600817. No abstract available.
- Individual participant dataSharing planned: No
Related trials for Primary Fibromyalgia
Not yet recruiting
Feasibility and Preliminary Effects of an Asynchronous Microlearning Intervention on Fibromyalgia Knowledge Among Primary Health Care Workers
Fibromyalgia, Fibromyalgia (FM)
Not yet recruitingObservational study
The Precision Mito- Mito Map COMPASS Study
Mitochondrial Diseases, Myalgic Encephalomyelitis Chronic Fatigue Syndrome
Not yet recruiting
Hyperthermia in Patients With Chronic Primary Pain - Effects on Thermoregulation, Somatosensory System and Movement Evoked Pain
Hyperthermia, Chronic Primary Pain
Recruiting
The Effect of Remote Electrical Neuromodulation (REN) on Conditioned Pain Modulation (CPM) in Migraine and Fibromyalgia
Migraine, Fibromyalgia
Recruiting
The Effect of Fermented Grape Juice Consumption on Fibromyalgia Patients
Fibromyalgia, Fibromyalgia (FM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Grünenthal Study Director study director
Grünenthal GmbH
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing GRT9906 in people with Primary Fibromyalgia, run by Grünenthal GmbH at 6 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 28 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Average Pain Intensity over last 3 days of treatment period (time frame: Last 3 days of treatment period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03783910, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Dec 2018.